Preview
Description
Stroke Ready is an offline educational reference for licensed clinicians and prehospital providers studying and recalling acute stroke care, both ischemic and hemorrhagic. It summarizes published guidelines, teaches classic vascular localization, and includes standard clinical scoring calculators, all on-device with no account and no network. It is built on the 2026 AHA/ASA acute ischemic stroke, 2022 AHA/ASA intracerebral hemorrhage, and 2023 AHA/ASA aneurysmal subarachnoid hemorrhage guidelines. Stroke Ready does not diagnose, image, or treat, and does not make time-critical decisions; those rest on the clinician's own examination, imaging, and current guidelines. LEARN LOCALIZATION Vascular-localization teaching aid: check the exam findings and risk factors, and it maps them to the territories they are classically associated with in vascular neuroanatomy, showing its full reasoning in a "Why this ranking" breakdown. It is a study aid, not a diagnosis. Nine classic ischemic syndromes: large-vessel occlusion, dominant and non-dominant MCA, ACA, PCA, brainstem/basilar, lateral medullary (Wallenberg), cerebellar, and lacunar, each with hallmark, vessel, signs, localizing pearls, workup, and mimics. Hemorrhagic and venous pathways: intracerebral hemorrhage, aneurysmal subarachnoid hemorrhage, and cerebral venous sinus thrombosis. CLINICAL SCORE CALCULATORS NIHSS, ICH Score, Hunt-Hess, WFNS, and modified Fisher: simple published scores with live totals and source links. They perform the same arithmetic as the paper forms. REFERENCE LIBRARY Work-up: imaging, labs, glucose, ECG/telemetry, pulse and access-site checks, and dysphagia screening, each with when to order and why. Protocols: EMS/prehospital, in-hospital stroke code, IV thrombolysis, and mechanical thrombectomy, as published checklists. Medications: dose, route, and frequency for thrombolytics, BP control, glucose, antiplatelet/DAPT, reversal, seizure, and osmotherapy. Tenecteplase shows both the guideline mg/kg dose and the FDA label's weight-band table side by side. Monitoring and neurochecks: schedules and targets drawn from the guidelines. Every entry cites its source. Fully offline; collects no data. IMPORTANT: Stroke Ready is an educational reference for licensed healthcare professionals. It is NOT a diagnostic device, NOT a substitute for clinical judgment, your stroke team, current guidelines, or facility protocols, and NOT for the general public. The localization teaching aid maps the findings you enter to classic associations and shows its reasoning; it does not diagnose, image, or confirm a stroke. Always seek a physician's advice and verify dosing against current references and pharmacist review before any medical decision. In an emergency, activate your facility Stroke Code or call 911.
What's New
Version 1.1 2026-09-24
The app is now named Stroke Ready, and this release applies a source-checked clinical content audit of its dosing, window and monitoring content. Changes affect...The app is now named Stroke Ready, and this release applies a source-checked clinical content audit of its dosing, window and monitoring content. Changes affect thrombolytic dosing, treatment-window labeling, anti-platelet eligibility and subarachnoid hemorrhage blood pressure. THROMBOLYTIC DOSING Tenecteplase now shows both dosing methods together: 0.25 mg/kg up to a maximum of 25 mg, per the 2026 AHA/ASA guideline and the pivotal trials, and the TNKase FDA label section 2 table, which assigns a fixed dose by weight band rather than by calculation. The label bands are shown in full: under 60 kg 15 mg (3 mL); 60 to under 70 kg 17.5 mg (3.5 mL); 70 to under 80 kg 20 mg (4 mL); 80 to under 90 kg 22.5 mg (4.5 mL); 90 kg and above 25 mg (5 mL). The app notes that the bands round up, so for most weights the labeled dose is higher than the mg/kg calculation (40 kg: 10 mg by calculation, 15 mg by label; 65 kg: 16.25 mg by calculation, 17.5 mg by label), and directs you to confirm which method your facility order set uses before drawing up. Both the Medications entry and the thrombolysis pathway carry this dual presentation. Alteplase remains 0.9 mg/kg to a maximum of 90 mg, with a 10 percent bolus over 1 minute and the remainder over 60 minutes. TREATMENT WINDOWS AND LABELING The thrombolysis pathway now carries a labeling caveat: both FDA labels indicate treatment within 3 hours of symptom onset. Activase: "Administer as soon as possible but within 3 hours after onset of symptoms." TNKase: "Initiate treatment as soon as possible and within 3 hours after the onset of stroke symptoms." Both thrombolytic entries state that treatment in the 3 to 4.5 hour window, and in the imaging-selected extended and wake-up windows, is guideline-endorsed but off-label for both agents. The guideline-based 4.5 hour window from last known well remains the app's core indication for eligible patients with a disabling deficit. ANTIPLATELET THERAPY Dual anti-platelet therapy eligibility now reads: minor non-cardioembolic stroke with NIHSS at or below 5, or high-risk TIA, started within 24 hours, per the 2026 AHA/ASA acute ischemic stroke guideline. Regimen is unchanged: clopidogrel 300 to 600 mg load then 75 mg daily with aspirin for 21 days, followed by single anti-platelet therapy. SUBARACHNOID HEMORRHAGE BLOOD PRESSURE The aneurysmal SAH monitoring card now states the 2023 AHA/ASA recommendation directly: control blood pressure with short-acting agents and avoid hypotension, hypertension and blood pressure variability before the aneurysm is secured. No numeric pre-securing target is given, because the 2023 guideline states that available evidence is insufficient to recommend any specific BP target. The card notes that SBP under 160 mmHg is a widely used institutional target and directs you to your own facility protocol. The Monitoring and Interventions screens now use consistent wording for pre-securing blood pressure. SOURCES Guideline citations re-verified as the current editions: 2026 AHA/ASA acute ischemic stroke, 2022 AHA/ASA intracerebral hemorrhage, 2023 AHA/ASA aneurysmal subarachnoid hemorrhage. New FDA label content is attributed inline to the TNKase and Activase prescribing information. Stroke Ready remains an educational reference, not a substitute for clinical judgment or facility protocol. Verify every dose independently before administration. Technical Analysis
Package Overview Basic metadata
Bundle ID
com.blackfoxmedia.strokeready Current Version 1.1
Minimum iOS 17.0
Package Size App Store Size
Package Metadata 0 / 0 version records
Detailed binary, privacy manifest, framework, and Info.plist results have not been indexed for this package yet. The verified App Store and archive metadata above remains available.
Known Version Records
0 version records with stored package metadata
Stored metadata does not guarantee a package is currently available to download.
| Details | Version / IDs | Version date | Action |
|---|